Literature DB >> 23619228

[The role of gut microbiota in the pathogenesis of obesity and diabetes].

Nina Stachowicz1, Anna Kiersztan.   

Abstract

The rapidly increasing number of people with obesity and type 2 diabetes is one of the most serious problems of the contemporary world. Until recently, it was thought that the main cause of this phenomenon is the change of lifestyle and dietary habits. According to recent reports, the gut microbiota may also play an important role in the "epidemic" of obesity and diabetes. Changes in its composition have been observed in people suffering from these diseases. In addition, the fact that the intestinal microbiota may affect body weight, insulin sensitivity or sugar and lipid metabolism has led to the hypothesis that these changes may contribute to the pathogenesis of obesity and diabetes. Scientists, using antibacterial drugs, pro- and prebiotics, are trying to modify the intestinal flora and thus affect its interaction with the host. The results are very promising, lead to further analysis and indicate gut microbiota as a potential therapeutic target for obesity and diabetes treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23619228     DOI: 10.5604/17322693.1044746

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  8 in total

1.  Insulin resistance is associated with specific gut microbiota in appendix samples from morbidly obese patients.

Authors:  Isabel Moreno-Indias; Lidia Sánchez-Alcoholado; Eduardo García-Fuentes; Fernando Cardona; Maria Isabel Queipo-Ortuño; Francisco J Tinahones
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

2.  Changes in intestinal microflora in rats with acute respiratory distress syndrome.

Authors:  Yan Li; Xiang-Yong Liu; Ming-Ming Ma; Zhi-Jiang Qi; Xiao-Qiang Zhang; Zhi Li; Guo-Hong Cao; Jun Li; Wei-Wei Zhu; Xiao-Zhi Wang
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 3.  Anti-obesity activity of the marine carotenoid fucoxanthin.

Authors:  Maria Alessandra Gammone; Nicolantonio D'Orazio
Journal:  Mar Drugs       Date:  2015-04-13       Impact factor: 5.118

4.  Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN).

Authors:  Maria De Angelis; Eustacchio Montemurno; Maria Piccolo; Lucia Vannini; Gabriella Lauriero; Valentina Maranzano; Giorgia Gozzi; Diana Serrazanetti; Giuseppe Dalfino; Marco Gobbetti; Loreto Gesualdo
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

Review 5.  Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges.

Authors:  Omotayo O Erejuwa; Siti A Sulaiman; Mohd S Ab Wahab
Journal:  Int J Mol Sci       Date:  2014-03-07       Impact factor: 5.923

Review 6.  Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus.

Authors:  Isabel Moreno-Indias; Fernando Cardona; Francisco J Tinahones; María Isabel Queipo-Ortuño
Journal:  Front Microbiol       Date:  2014-04-29       Impact factor: 5.640

7.  Changes in intestinal microflora of Caenorhabditis elegans following Bacillus nematocida B16 infection.

Authors:  Qiuhong Niu; Lin Zhang; Keqin Zhang; Xiaowei Huang; Fengli Hui; Yunchao Kan; Lunguang Yao
Journal:  Sci Rep       Date:  2016-02-02       Impact factor: 4.379

8.  Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection.

Authors:  Paulina Konrad; Jan Chojnacki; Anita Gąsiorowska; Cezary Rudnicki; Aleksandra Kaczka; Cezary Chojnacki
Journal:  Prz Gastroenterol       Date:  2018-03-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.